{"filing":{"accession_number":"0001193125-26-401157","cik":"0001070494","ticker":"ACAD","company_name":"ACADIA PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-09-24","report_date":"2026-09-24","primary_document":"d168737d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1070494/000119312526401157/d168737d8k.htm"},"events":[{"id":34957,"run_id":32189,"accession_number":"0001193125-26-401157","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Acadia announced Phase 2 topline results from the RADIANT clinical trial of remlifanserin for Alzheimer's disease psychosis. The trial narrowly missed its primary endpoint (p=0.0603) but achieved significance on a key secondary endpoint (p=0.0077); the company plans to continue Phase 3 development with protocol amendments including removal of the 30 mg dosage arm.","company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","filing_date":"2026-09-24","form":"8-K","submitted_at":null,"items":[{"id":38850,"accession_number":"0001193125-26-401157","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Acadia announced Phase 2 topline results from the RADIANT clinical trial of remlifanserin for Alzheimer's disease psychosis, narrowly missing the primary endpoint (p=0.0603) but achieving significance on a key secondary endpoint (p=0.0077). The company plans to continue Phase 3 development with protocol amendments. This is a material clinical development milestone for a mid-to-late-stage pipeline program in a high-unmet-need indication, disclosed under Item 7.01 (Regulation FD Disclosure) rather than as a formal earnings release, making it an operational/strategic business event rather than a financial result.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T21:12:50.092660+00:00","company_name":"","ticker":null,"filing_date":""},{"id":38851,"accession_number":"0001193125-26-401157","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"ACADIA announced Phase 3 enabling topline results from the Phase 2 RADIANT clinical trial of remlifanserin for Alzheimer's disease psychosis. The primary endpoint narrowly missed statistical significance (p=0.0603), but a key secondary endpoint achieved nominal significance (p=0.0077). The company plans to continue Phase 3 enrollment with protocol amendments, including removal of the 30 mg dosage arm. This is a material clinical development milestone that would affect investor assessment of the company's pipeline progress, but it does not fit neatly into earnings_release (no financial results), material_litigation, or other specific categories—it is a clinical trial result announcement that is operational/strategic in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T21:12:50.092660+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":38850,"accession_number":"0001193125-26-401157","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Acadia announced Phase 2 topline results from the RADIANT clinical trial of remlifanserin for Alzheimer's disease psychosis, narrowly missing the primary endpoint (p=0.0603) but achieving significance on a key secondary endpoint (p=0.0077). The company plans to continue Phase 3 development with protocol amendments. This is a material clinical development milestone for a mid-to-late-stage pipeline program in a high-unmet-need indication, disclosed under Item 7.01 (Regulation FD Disclosure) rather than as a formal earnings release, making it an operational/strategic business event rather than a financial result.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T21:12:50.092660+00:00","company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","filing_date":"2026-09-24"},{"id":38851,"accession_number":"0001193125-26-401157","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"ACADIA announced Phase 3 enabling topline results from the Phase 2 RADIANT clinical trial of remlifanserin for Alzheimer's disease psychosis. The primary endpoint narrowly missed statistical significance (p=0.0603), but a key secondary endpoint achieved nominal significance (p=0.0077). The company plans to continue Phase 3 enrollment with protocol amendments, including removal of the 30 mg dosage arm. This is a material clinical development milestone that would affect investor assessment of the company's pipeline progress, but it does not fit neatly into earnings_release (no financial results), material_litigation, or other specific categories—it is a clinical trial result announcement that is operational/strategic in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-24T21:12:50.092660+00:00","company_name":"ACADIA PHARMACEUTICALS INC","ticker":"ACAD","filing_date":"2026-09-24"}]}